- Cetuximab in combination with radiotherapy is recommended as a treatment option only for patients with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.
- People currently receiving cetuximab in combination with radiotherapy for the treatment of locally advanced squamous cell cancer of the head and neck who do not meet the criteria outlined in section 1.1 should have the option to continue therapy until they and their clinicians consider it appropriate to stop
Note that this document does not constitute the Institute's formal guidance on this technology. The recommendations made in Section 1 are preliminary and may change after consultation.
The key dates for this appraisal are:
Closing date for comments: 4 March 2008
Next Appraisal Committee meeting: 12 March 2008
- UK's NICE backs ImClone's Erbitux, changes tack Reuters - USA
Vinod Joshi of the Mouth Cancer Foundation said the about-turn by NICE was a "happy day" for patients since Erbitux, known generically as cetuximab, ...